Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $221.37 billion. The enterprise value is $247.35 billion.
| Market Cap | 221.37B |
| Enterprise Value | 247.35B |
Important Dates
The last earnings date was Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | Mar 12, 2025 |
Share Statistics
Novartis AG has 1.96 billion shares outstanding. The number of shares has decreased by -2.90% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.96B |
| Shares Change (YoY) | -2.90% |
| Shares Change (QoQ) | -1.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.87B |
Valuation Ratios
The trailing PE ratio is 17.74 and the forward PE ratio is 12.74.
| PE Ratio | 17.74 |
| Forward PE | 12.74 |
| PS Ratio | 4.16 |
| Forward PS | 5.45 |
| PB Ratio | 5.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.57 |
| P/OCF Ratio | 11.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.20, with an EV/FCF ratio of 14.05.
| EV / Earnings | 19.24 |
| EV / Sales | 4.65 |
| EV / EBITDA | 11.20 |
| EV / EBIT | 13.93 |
| EV / FCF | 14.05 |
Financial Position
The company has a current ratio of 0.79, with a Debt / Equity ratio of 0.81.
| Current Ratio | 0.79 |
| Quick Ratio | 0.50 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 1.40 |
| Debt / FCF | 1.78 |
| Interest Coverage | 16.83 |
Financial Efficiency
Return on equity (ROE) is 32.89% and return on invested capital (ROIC) is 16.23%.
| Return on Equity (ROE) | 32.89% |
| Return on Assets (ROA) | 11.42% |
| Return on Invested Capital (ROIC) | 16.23% |
| Return on Capital Employed (ROCE) | 25.98% |
| Revenue Per Employee | $701,369 |
| Profits Per Employee | $169,458 |
| Employee Count | 75,883 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, Novartis AG has paid $2.06 billion in taxes.
| Income Tax | 2.06B |
| Effective Tax Rate | 13.80% |
Stock Price Statistics
The stock price has increased by +16.28% in the last 52 weeks. The beta is 0.53, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +16.28% |
| 50-Day Moving Average | 110.42 |
| 200-Day Moving Average | 108.98 |
| Relative Strength Index (RSI) | 56.61 |
| Average Volume (20 Days) | 2,404,944 |
Short Selling Information
The latest short interest is 4.51 million, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 4.51M |
| Short Previous Month | 4.02M |
| Short % of Shares Out | 0.23% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.48 |
Income Statement
In the last 12 months, Novartis AG had revenue of $53.22 billion and earned $12.86 billion in profits. Earnings per share was $6.38.
| Revenue | 53.22B |
| Gross Profit | 40.28B |
| Operating Income | 17.75B |
| Pretax Income | n/a |
| Net Income | 12.86B |
| EBITDA | 22.09B |
| EBIT | 17.75B |
| Earnings Per Share (EPS) | $6.38 |
Balance Sheet
The company has $7.18 billion in cash and $31.27 billion in debt, giving a net cash position of -$24.09 billion or -$12.30 per share.
| Cash & Cash Equivalents | 7.18B |
| Total Debt | 31.27B |
| Net Cash | -24.09B |
| Net Cash Per Share | -$12.30 |
| Equity (Book Value) | 38.45B |
| Book Value Per Share | 19.58 |
| Working Capital | -6.51B |
Cash Flow
In the last 12 months, operating cash flow was $19.00 billion and capital expenditures -$1.39 billion, giving a free cash flow of $17.61 billion.
| Operating Cash Flow | 19.00B |
| Capital Expenditures | -1.39B |
| Free Cash Flow | 17.61B |
| FCF Per Share | $8.99 |
Margins
Gross margin is 75.68%, with operating and profit margins of 33.35% and 24.16%.
| Gross Margin | 75.68% |
| Operating Margin | 33.35% |
| Pretax Margin | 28.03% |
| Profit Margin | 24.16% |
| EBITDA Margin | 41.50% |
| EBIT Margin | 33.35% |
| FCF Margin | 33.08% |
Dividends & Yields
This stock pays an annual dividend of $3.99, which amounts to a dividend yield of 3.53%.
| Dividend Per Share | $3.99 |
| Dividend Yield | 3.53% |
| Dividend Growth (YoY) | 5.74% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 62.63% |
| Buyback Yield | 2.90% |
| Shareholder Yield | 6.43% |
| Earnings Yield | 5.81% |
| FCF Yield | 7.95% |
Analyst Forecast
The average price target for Novartis AG is $123.67, which is 9.34% higher than the current price. The consensus rating is "Hold".
| Price Target | $123.67 |
| Price Target Difference | 9.34% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 2.63% |
| EPS Growth Forecast (5Y) | 10.61% |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novartis AG has an Altman Z-Score of 3.71 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.71 |
| Piotroski F-Score | 6 |